Nido Biosciences announced it will close after its lead neurological disease candidate failed to produce meaningful benefit in a midstage (phase 2) study. The company’s decision ends a five‑year attempt to commercialize the program and highlights the development risk endemic to small neuro‑focused biotechs. Coverage of the closure notes employees and investors face asset wind‑down and that any remaining data may be licensed or archived. The outcome underlines persistent translational hurdles in neurology and the need for robust go/no‑go criteria at early clinical stages.